This Week in Nephrology — Jul 29, 2026

Welcome to This Week in Nephrology. This week we're covering 9 notable papers spanning cardiovascular-kidney-metabolic health, glomerular diseases and transplantation, and acute kidney injury and rare disorders. Let's dive in.

We begin with the expanding sphere of cardiorenal medicine, where a major report from the International Society of Nephrology published in Kidney International outlines the new Cardiovascular-Kidney-Metabolic framework, emphasizing that early, integrated case-finding and joint risk assessment are essential to halt disease progression [1]. Building on this systems-level perspective, a retrospective study in the Clinical Journal of the American Society of Nephrology evaluated adults with primary aldosteronism treated with mineralocorticoid receptor antagonists and found that adding a sodium-glucose cotransporter-2 inhibitor was associated with a substantially lower risk of all-cause mortality, major adverse cardiovascular events, and major adverse kidney events [4]. Looking closely at how these agents protect the kidney, a proteomic analysis of the DAPA-CKD trial published in Kidney International measured over 3,000 circulating proteins and revealed that dapagliflozin modifies pathways related to extracellular matrix remodeling, inflammation, and fibrosis, with kidney injury molecule-1 showing the single strongest reduction [3]. Together, these findings support aggressive, mechanism-based combination therapy to intercept cardiorenal decline across diverse patient populations.

Turning to immunology and transplantation, a large observational cohort study across six centers in the United States and Europe published in Kidney International examined acute T cell-mediated rejection in kidney allografts and reported that roughly one in eight patients developed rejection within the first year [2]. Despite treatment, over one-third of patients experienced clinical deterioration and nearly a third had persistent rejection on follow-up biopsy, with persistent inflammation conferring a more than tripled risk of graft loss [2]. In another glomerular disease analysis from the Cure Glomerulonephropathy cohort published in Kidney International Reports, researchers investigated IgA nephropathy and found that mesangial and capillary immunodeposits strongly correlated with proliferative lesions and urinary membrane attack complex levels, which were independently associated with long-term loss of estimated glomerular filtration rate [5]. Challenging traditional paradigms in pediatric nephrology, a multi-national study in Kidney International evaluated children with genetic podocytopathies treated with calcineurin inhibitors and found that while most patients were non-responders, those achieving a sustained response experienced superior kidney survival with zero instances of kidney failure during follow-up, suggesting that a clinical trial of calcineurin inhibitors remains warranted in these genetic cohorts [7].

Finally, we examine critical care nephrology and rare inherited tubulopathies. A prospective study in Kidney360 evaluated patients with septic shock-associated acute kidney injury and tracked seven different uremic toxins daily, demonstrating that while toxin levels accumulated significantly in severe injury and showed variable clearance during kidney replacement therapy, their trajectories were not independently associated with twenty-eight-day mortality or organ support dependence [8]. In another study from Kidney360 focusing on rare genetic disorders, investigators evaluated patients with adenine phosphoribosyltransferase deficiency and showed that tissue burden of 2,8-dihydroxyadenine crystals directly correlated with marked inflammation, tubular atrophy, and interstitial fibrosis, alongside immunohistochemical markers confirming early fibrotic remodeling and crystal-induced injury [9]. Meanwhile, evaluating biomarker precision in autosomal dominant polycystic kidney disease, a study in Kidney360 demonstrated that a combined creatinine-cystatin C equation was the least biased and most precise estimating method when compared to measured iothalamate clearance [6].

If you only have time for one paper this week, make it the international cohort study on early acute T cell-mediated rejection in kidney allografts published in Kidney International [2]. This study is our top pick because it shatters the misconception that early acute T cell-mediated rejection is clinically benign, proving that treatment resistance is common and that persistent histological inflammation is a major, independent driver of long-term graft loss that demands response-guided surveillance protocols [2].

Here are the key takeaways from this week in Nephrology. Sodium-glucose cotransporter-2 inhibitors added to mineralocorticoid receptor antagonists significantly lower mortality, major adverse cardiovascular events, and major adverse kidney events in primary aldosteronism [4]. Dapagliflozin exerts protective renal effects by modifying circulating proteins and pathways linked to inflammation, extracellular matrix remodeling, and fibrosis [3]. Early acute T cell-mediated rejection in kidney transplantation frequently resists treatment, and persistent histological inflammation carries a high risk of long-term graft failure [2]. In IgA nephropathy, urinary membrane attack complex and mesangial immunodeposits correlate with proliferative lesions and independently predict estimated glomerular filtration rate decline [5]. Finally, a subset of children with genetic podocytopathies exhibit sustained clinical responses to calcineurin inhibitors and achieve excellent long-term kidney survival [7].

That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.